Extension in AS: Sustainability of Benefits, Safety and Tolerability (MEASURE 1 ext)
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Sponsor: Novartis Pharmaceuticals
This PHASE3 trial investigates Spondylitis, Ankylosing and is currently completed. Novartis Pharmaceuticals leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Berlin, Germany , Bordeaux, France , Brescia, Italy , Brussels, Belgium , Burgas, Bulgaria , Cambridge, United Kingdom , Catania, Italy , Cologne, Germany , Culiacán, Mexico and 43 more locations